Public confidence in the FDA is experiencing unprecedented decline as tensions between agency leadership and scientific staff intensify. Patients facing limited treatment alternatives are witnessing institutional challenges that threaten regulatory credibility built over decades. This erosion of trust raises critical questions about drug approval processes, food safety oversight, and the agency's ability to balance innovation with consumer protection in an increasingly polarized environment.

Summary auto-generated by AI from the original publisher's content. Editorial standards.